Japan approves price cut for Alzheimer's drug Lecanemab
The decision is based on an assessment by the Central Social Insurance Medical Council that cited the low cost-effectiveness of the drug used to treat dementia caused by Alzheimer's disease.
The price of the drug will be lowered to ¥97,277 for a 500-milligram bottle. Dosages are based on weight. For example, a patient weighing 50 kilograms would see an annual cost reduction from about ¥2.98 million to about ¥2.53 million.
Lecanemab is said to be innovative because it removes abnormal proteins that accumulate in patients' brains, and it is expected to slow the progression of the disease.
The medication was subject to a system that adjusts drug prices based on cost-effectiveness for high-priced or large-market drugs.
At a meeting in July, the council described Lecanemab as having low cost-effectiveness compared with existing treatments.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
NHK
2 days ago
- NHK
Clinics across Japan report increase in COVID-19 patients
Medical institutions in Japan have been seeing more people infected with the coronavirus, with the average number of patients per institution topping five for the first time since February. The Japanese health ministry on Friday released a weekly report on the number of COVID-19 patients who visited about 3,000 clinics across the country for the week ending Sunday. The ministry said 21,365 people had been confirmed infected. The figure was an increase of 5,441 people from a week before. The average number of coronavirus patients per institution was 5.53. That's 1.34 times higher than the previous week and marks the seventh consecutive weekly increase. The average rose in all of Japan's 47 prefectures except Okinawa. Miyazaki had the highest number at 14.07, followed by Okinawa with 12.73, Kagoshima with 12.68, Kumamoto with 9.58 and Saga with 8.75. Reports from about 500 medical institutions showed 1,501 coronavirus patients had been hospitalized during the week. That's 314 more than the previous week. Health ministry officials say an increase in the number of COVID-19 patients has been seen every summer. The officials urge people to take preventive measures, such as washing hands and ventilating indoor spaces. They also recommend wearing masks when meeting elderly people and those with underlying conditions.
Japan Times
2 days ago
- Japan Times
Chugai stock drops the most since 1977 on disappointing obesity drug data
Shares in Chugai Pharmaceutical tumbled the most since 1977 after late-stage trial data on an obesity drug it licensed to Eli Lilly & Co. showed disappointing results. The stock price of Japan's largest drugmaker sank as much as 20% in Tokyo on Friday, wiping out over $16 billion in market value, or ¥1,458 ($9.89) per share, after the drug's study resulted in lower weight loss and higher rates of nausea and vomiting than anticipated. Patients on the highest dose of the drug lost 12.4% weight, lower than 15% achieved by patients on a pill developed by rivals Novo Nordisk, wrote Jefferies Japan analysts Stephen Barker and Miyabi Yamanaka. "With efficacy and safety levels at the lower end of market expectations, Lilly's share price was down 14.5% on the day. Assuming 30% of the ¥14 trillion drop in Lilly's market capitalization corresponds to Chugai royalties, we put related downside risk for Chugai at ¥2,300,' said Citi analyst Hidemaru Yamaguchi. "The results have not led to a big differentiation with rival pills,' Hiroyuki Matsubara, an analyst at Nomura Securities, wrote in a note. On Wall Street, Eli Lilly's share prices fell 14% on the news while Novo Nordisk's shares in Denmark jumped 6.7%.
Japan Times
2 days ago
- Japan Times
Tokyo temporarily halts medical helicopter operations due to staff shortage
Tokyo has temporarily halted the operations of its emergency medical helicopter, also known as a doctor helicopter, in the capital since Thursday, due to a shortage of staff. The suspension began on Thursday and will continue through Sunday. The helicopter will also be out of service between Aug. 24 and Aug. 26. Doctor helicopters, or doctor-heli for short, are used to transport emergency medical patients in cases when transport is more efficient via air than with a typical ambulance. According to the Tokyo Metropolitan Government, Tokyo runs its doctor helicopter program in cooperation with Kyorin University Hospital, which entrusts the operation of the aircraft to Kobe-based air training institute Hirata Gakuen. Hirata Gakuen was unable to secure mechanics during the upcoming periods of suspension due to a shortage of staff caused by multiple mechanics leaving their jobs at the same time. The institute is in the process of hiring more staff and is set to resume a full operating schedule by next month. Although the helicopter can be deployed all across the capital, it is primarily used in the mountainous Tama district in western Tokyo, in places where it is deemed that air travel is more practical. According to the latest data released by the metropolitan government, it was deployed 1,360 times in fiscal 2023. During the temporary suspension, Tokyo will utilize ambulances to ensure that patients are able to receive medical attention as soon as possible in close cooperation with the fire department, an arrangement that is also in place during normal operation and when bad weather hampers flights. The staff shortage at Hirata Gakuen causing these suspensions is temporary. However, the metropolitan government says it has noticed a chronic shortage of mechanics for services such as doctor helicopter maintenance and operation, not just in Tokyo but around the country. Each prefecture typically relies on a single organization to operate its doctor helicopters, and in some cases, retired staff have had to extend their retirement age to fill in. As demand for services like doctor helicopters continues to increase, especially with the frequent natural disasters in the country, the transport ministry has been working to increase the number of pilots and train more mechanics in the aviation industry, with an expert panel having issued a final report on future plans earlier this year.
